Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Jan 04, 2023 1:11pm
165 Views
Post# 35203046

RE:Stocktwits continues to lose followers

RE:Stocktwits continues to lose followers

This letter was a step in the right direction so hopefully we will see more of the same going forward but if the communication's purpose is to catch the attention of more interested investors resulting in higher demand/liquidity and valuation then it has strategically balanced. You need to know your targeted market which shouldn't be limited to one specific section of the market for instance Cantor came out with a new repot today (below) but that has its own limitations,where to reach them, what to say, when and how often.
On who your target is if Stocktwits PRs presented on their own website, Yahoo Finance and their social media platforms have limitations instead they should use other channels followed by much broader audience. On what to say they need to stop overselling some aspects of their business and underselling others for instance in the last few years at first they oversold the commercial assets then it was shifted to the R&D now back to commercial the results are the TH1902 was " the only reason one has to be invested in THTX" and after the pause the valuation was cut by half. I do understand when you market you start with the current most valuable asset but other assets which can add value has to be marketed in THTX's case both legacy drugs and NASH why because they have both potential very promising prospects. On when and how often I would say as frequently as possible/necessary and whether there are any new developments or not so the story stays current and not sit on the news for months like the positive results from 1a trial, what was the logic behind that?
Point is I believe the communication is an important part which can support the valuation and IS something they have control of and should be improved for many reasons especially in THTX's case and current situation.
https://www.streetinsider.com/dr/news.php?id=21030193



PWIB123 wrote: Stocktwits followers are now at the lowest I've seen it in a very long time, around a dozen less than before the "pause" announcement.  When the value proposition was actually improving due to the steep decline in share price compared to a fairly stable fundamental profile, the number of followers interested in the stock was also in decline.  Paul's a sales guy.  I think of followers as potential customers who could buy your company's stock.  They don't have to.  They have many options.  What are you providing for them to convince them they should buy your stock instead of someone else's?  You should also think of followers as your sales team.  They are a free sales team willing and able to generate enormous leads that can result in millions of new investors.  If they believe, they will tell the world on your behalf.  All you have to do is guide them, and they'll do the work.  By the way, a lot of these followers are uneducated investors who will no doubt get your messaging entirely wrong.  My experience says it doesn't matter.  Followers arguing with each other over details usually results in more interested parties following the story.  Just start communicating!  Stocktwits and the followers on other discussion boards is a barometer to shareholder engagement.  

 

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse